Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
A provision in new German legislation that requires insurance funds to consider a variety of suppliers will do nothing to address drug shortages because it is not obligatory, local industry association Pro Generika believes.
Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.
Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.
Firms now have until 23 August to enter the Global Generics & Biosimilars Awards 2019.
Sandoz expects to bring an expedited appeal against a US district court’s finding that two patents protecting Amgen’s Enbrel etanercept brand until 2028 and 2029 are valid.
International off-patent industry body the IGBA has urged Australia’s government to “hold firm” against intellectual-property proposals made by the European Commission as part of negotiations over an Australia-EU trade deal. The organization believes the EU proposals would negatively impact access to generics and biosimilars in Australia.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.